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ABSTRACT
Background: Galectin-3 is a β-galactoside-binding protein which is implicated in diverse physiological and
pathological processes including human liver cirrhosis and a mouse lung fibrosis model. The aim of this study is
to determine whether galectin-3 is involved in human lung fibrosis.
Methods: We measured galectin-3 concentration in bronchoalveolar lavage fluid (BALF) and examined its ex-
pression in alveolar macrophages from patients with interstitial lung disorders using ELISA and immunohisto-
chemical staining, respectively. Using monocytemacrophage cell lines in vitro, we examined the effect of cy-
tokines on galectin-3 expression, and the opposite similarly by RT-PCR and Western blotting. Finally, we per-
formed Micro Boyden chamber assay and Sircoll assay to determine whether galectin-3 induces migration and
collagen synthesis, respectively, in fibroblasts.
Results: Galectin-3 was specifically increased in BALF from patients with idiopathic pulmonary fibrosis (IPF)
and interstitial pneumonia associated with collagen vascular disease (CVD-IP). Galectin-3 levels in BALF
seemed to be lower in IPF and CVD-IP patients receiving corticosteroid therapy. Alveolar macrophages from
IPF patients expressed more galectin-3 compared with those from control. Galectin-3 expression was induced
by tumor necrosis factor-alpha (TNF-α) and interferon (IFN)-γ in a monocytic cell line U937. Galectin-3 also in-
duced mRNA expression and protein production of TNF-α and interleukin (IL)-8 in a macrophage cell line THP-
1. This lectin stimulated NIH-3T3 fibroblast to induce migration and collagen synthesis in vitro.
Conclusions: These results suggest that galectin-3 is involved in the pathogenesis of human IPF and CVD-IP
by activating macrophages and fibroblasts.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic inter-
stitial lung disorder with high lethality. Current con-
ventional therapies by corticosteroids and immuno-
suppressive agents usually have little effect on the
natural course of IPF. The pathophysiology is de-
scribed as usual interstitial pneumonia (UIP), charac-
terized by endothelial or epithelial cell injury with ac-
cumulation of inflammatory cells, followed by deposi-
tion of extracellular matrix (ECM) and fibroblast acti-
vation, resulting in end-stage fibrosis.1-3 These re-
sponses are mediated by various cytokines, chemoki-
nes, and growth factors, including tumor necrosis
factor-alpha (TNF-α),4-7 transforming growth factor-
beta (TGF-β),8,9 and platelet-derived growth factor
(PDGF).10,11 Recent studies demonstrated that angio-
genic C-C chemokines and T helper type 2 (Th2) cy-
tokines also play important roles in IPF.12-14 Dysregu-
lation of the expression of these factors is speculated
to be responsible for the maintenance of tissue injury
and fibrosis of the disease, although the precise
mechanism remains uncertain.
Galectin-3 belongs to a family of β-galactoside-
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binding animal lectins.15 It is secreted by various cell
types including monocytes, macrophages and epithe-
lial cells.16,17 The released protein can function as an
extracellular molecule to activate cells,18-23 mediate
cell-cell and cell-ECM interactions,24-26 induce migra-
tion of various types of cell,27,28 and negatively regu-
late T cell receptor signaling.29 This protein is also
found abundantly inside cells and has been shown to
play critical roles in some biological responses
through its intracellular actions.30-35 There are only a
few reports which suggest a possible role of this
lectin in human pathological fibrotic remodeling such
as human liver cirrhosis.36 Nevertheless, galectin-3
was shown to be increased in a mouse model of
bleomycin-induced lung fibrosis,37 suggesting partici-
pation of the protein in the pathogenesis of human
lung fibrosis by its variegated effects. Therefore, we
aimed to determine the role of galectin-3 in human
lung fibrosis, and its biological activity on macro-
phages and fibroblasts.
METHODS
Materials. Recombinant human galectin-3,38 mouse
mAb against galectin-3 (B2C10), and polyclonal goat
anti-galectin-3 Ab39 were prepared as described previ-
ously. Recombinant TNF-α, IL-4, IL-13, IFN-γ, TGF-β,
lipopolysaccharide (LPS), and all other reagents were
purchased from Sigma (St. Louis, MO, USA) unless
otherwise stated.
Preparation of human bronchoalveolar lavage fluid
and alveolar macrophages. Human bronchoalveolar
lavage fluid (BALF) and alveolar macrophages were
obtained using a bronchoscope according to a previ-
ously described protocol.6 Samples were collected
from 41 patients who were treated for various lung
disorders in the Department of Internal Medicine,
Toho University Sakura Medical Center, after obtain-
ing informed consent (patients’ mean age 57.9, 26―86
years; male : female = 20 : 21). Diagnoses of IPFUIP
and cryptogenic organizing pneumoniabronchiolitis
obliterance organizing pneumonia (COPBOOP) was
made by the respiratory disease group of the hospi-
tal, according to the criteria of the American Thoracic
Society (ATS)European Respiratory Society (ERS)
International Multidisciplinary Consensus Classifica-
tion of the Idiopathic Interstitial Pneumonias (IIPs).1
Non-IIP diffuse parenchymal lung diseases including
interstitial pneumonia associated with collagen vascu-
lar disease (CVD-IP), hypersensitive pneumonia
(HP), and Pneumocystis jiroveci infection were diag-
nosed clinically, radiologically, and pathologically. In
the case of CVD-IP, we only examined the samples
from patients who showed non-specific interstitial
pneumonia (NSIP) patterns with typical radiological
features and high resolution computed tomography
(HRCT) findings (peripheral ground glass and reticu-
lar opacity without eminent honeycombing) accord-
ing to the ATSERS Classification.1
Immunohistochemistry cell staining. Alveolar macro-
phages from BALF adhering on coverslips were used
in immunofluorescence microscopic analysis accord-
ing to previously described methods.35 The purity of
the macrophages was more than 90%, and the viabil-
ity was more than 99%. Briefly, after fixation with 4%
paraformaldehyde in PBS, the cells were permeabi-
lized with 0.2% Triton X-100PBS, incubated with goat
anti-galectin-3 Ab followed by rabbit anti-goat Ab con-
jugated to Alexa 488 (Molecular Probes Inc. Eugene,
OR, USA). The coverslips were mounted on glass
slides and digital images from a fluorescence micro-
scope were captured.
Preparation of cultured cell lines. The human mono-
cytic THP-1 and U937 cell lines (American Type Cul-
ture Collection, Manassas, VA, USA) and NIH-3T3 fi-
broblast cell line were cultured in RPMI 1640 me-
dium supplemented with 10% fetal calf serum (FCS)
(Gibco BRL, Gaithersburg, MD, USA) and 2% L-
glutamine at 37℃ in a humidified atmosphere of 5%
CO2. For the induction of the THP-1 cells to differen-
tiate into macrophages, the cells (5 × 105 to 106 per
ml) were seeded in the same medium containing 10
nM phorbol myristate acetate (PMA) for 24 hours. Af-
ter removing the nonattached cells, adhered cells
were washed with RPMI 1640 three times. These
cells were incubated overnight in RMPI 1640 medium
with 0.1% FCS before use.
RT-PCR for mRNA detection. To examine mRNA
expression, cells were stimulated with various re-
agents for 1 hour, washed with cold PBS three times,
and total mRNA was extracted using ISOGEN Poly
(A) + Isolation Pack (Wako Pure Chemical Indus-
tries, Ltd., Osaka, Japan). After cDNA was prepared
using a cDNA synthesis kit (Roche Diagnostics Ltd,
Basel, Switzerland), RT-PCR was performed as de-
scribed previously.39 Briefly, 2 μl of cDNA was added
to a mixture of 1 × PCR buffer (Perkin-Elmer, Welle-
sley, MA, USA), 2 mM of MgCl2, 0.2 mM of each
dNTP, 0.4 mM of each specific primer, and 1.25 U
Taq polymerase (Perkin-Elmer) in a final volume of
50 μl. The PCR primer pairs for cytokines were as fol-
lows: TNF-α sense oligonucleotide 5’-GAGTGACAAG
CCTGTAGCCCATGTTGTAGCA-3’, and antisense
oligonucleotide 5’-GGCAATGATGATCCCAAAGTA
GACCTGCCCAGACT-3’; IL-8 sense nucleotide 5’-A
TGACTTCCAAGCTGGCCGTGGCT-3’ and antisense
nucleotide 5’-TTCTCAGCCCTCTTCAAAAACTTCT
C-3’; an internal control G3PDH sense nucleotide 5’-
TGAAGGTCGGAGTCAACGGATTTGGT-3’ and an-
tisense nucleotide 5’-CATGTGGGCCATGAGGTCCA
CCAC-3’. The PCR cycle consisted of denaturation at
94℃ for 45 seconds, annealing at 60℃ for 45 sec-
onds, and extension at 72℃ for 2 minutes, for 25 cy-
cles. The DNA products obtained were separated by
electrophoresis in 3% agarose gel containing ethid-
ium bromide for visualization.
Western blotting and ELISA assay. Concentration of
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Table 1 Properties of the BALF from patients.
 Cel Diferentiation (%)Total Cels
(×104/ml)
Patients
n EoPMNLyAM
1.36 ± 0.442.81 ± 0.994.67 ± 1.3891.1 ± 2.273.16 ± 0.44 8IPF/UIP
11.7 ± 5.336.96 ± 2.5620.0 ± 5.6561.4 ± 8.063.67 ± 0.6817CVD-IP (NSIP patern)
0.76 ± 0.263.76 ± 1.6834.3 ± 12.061.1 ± 10.95.30 ± 1.20 5COP/BOOP
1.53 ± 0.741.93 ± 1.1668.6 ± 13.027.3 ± 13.012.2 ± 4.07 3HP
0.70 ± 0.300.80 ± 0.8027.6 ± 16.570.1 ± 15.26.95 ± 4.65 2P. jiroveci
0.17 ± 0.171.50 ± 0.657.00 ± 1.7891.2 ± 2.501.46 ± 0.55 6control
　Definition of abbreviations: IPF＝idiopathic pulmonary fibrosis; UIP＝usual interstitial pneumonia; CVD-IP＝interstitial pneumonia 
associated with colagen vascular disease; NSIP＝ non-specific interstitial pneumonia; COP＝ cryptogenic organizing pneumonia; 
BOOP＝ bronchiolitis obliterance organizing pneumonia; HP＝ hypersensitive pneumonia; P. jiroveci＝ Pneumocystis jiroveci 
infection.
galectin-3 in BALF was measured by ELISA assay us-
ing anti-galectin-3 Ab according to previously de-
scribed methods.41 For in vitro experiments, U937
cell suspension (5 × 106ml) was stimulated with
various cytokines including TNF-α, IFN-γ, IL-4, IL-13,
or TGF-β. After incubation at 37℃ for 24 hours, cells
were centrifuged, placed on ice, washed twice with
cold PBS, and lysed in NP-40 lysing buffer (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM
EDTA, 5 mM sodium pyrophosphate, 1 mM Na3VO4,
10 μgml leupeptin, 10 μgml aprotinin) on ice for 30
minutes. After the lysates were centrifuged at 10,000
g for 10 minutes at 4℃, the protein concentration was
measured using DC Protein Assay (Bio-Rad, Hercu-
les, CA, USA). For immunoblotting, 30―100 μg of to-
tal protein in each lysate was applied to SDS-PAGE
and the separated proteins were transferred to a
PVDF membrane (Millipore, Bedford, MA, USA).
The membranes were blocked with skim milk, im-
munoblotted with B2C10, an anti-galectin-3 mAb, and
visualized using the ECL system (Amersham Phar-
macia Biotech Inc, Piscataway, NJ, USA). In the case
of adhered THP-1 cells, the supernatant was also col-
lected after the indicated time of galectin-3 stimula-
tion, and the concentrations of several cytokines and
chemokines were measured by ELISA kit.
Migration assay in vitro. Fibroblast migration was
examined using 96-well modified micro-Boyden
chambers with 5 μm pore size filters (Neuro Probe,
Gaithersburg, MD, USA) as described previously.27
Briefly, after the indicated concentrations of galectin-
3 or LPS prepared in HBSS with Ca2+ and Mg2+ were
applied to the lower chambers, NIH-3T3 fibroblast
suspensions (2.5―5.0 × 104 cellswell) were applied to
the upper chambers. After incubation for 1 hour in a
humidified incubator at 37℃ in 5% CO2, the mem-
branes were washed once with PBS. After the upper
side was wiped with paper, the membranes were
processed with Wright stain to visualize migrated fi-
broblasts to the bottom side. The numbers of mi-
grated fibroblasts on the filters were counted in 5―10
high power fields. Fibroblast migration was calcu-
lated from the average numbers of the counted cells
and expressed as a percentage of seeded cells in each
well.
Detection of collagen synthesis. To examine the ef-
fect of galectin-3 on collagen synthesis by fibroblasts,
Sircol collagen assay (Biocolor Ltd., Newtownabbey,
Northern Ireland) was performed according to the
manufacturer’s instructions. Briefly, adhered NIH-3T3
cells were stimulated with galectin-3 or rhIL-4 (posi-
tive control) for 48 hours, and the supernatant was
collected and assayed in triplicate.
Data analysis. Data are presented as means ± SD
unless otherwise stated. Statistical analyses of the re-
sults were performed by ANOVA using Fisher’s pro-
tected least significant difference test for multiple
comparisons. P values less than 0.05 were considered
to indicate significant differences.
RESULTS
Galectin-3 was increased in BALF from patients with
lung fibrosis. To determine the relationship between
galectin-3 and fibrotic lung disease, we first measured
the galectin-3 concentrations in BALF from patients
with various interstitial lung disorders. As shown in
Table 1, BALF samples were collected from healthy
sites of the lung in 6 patients with lung cancer as con-
trol, and from those of pathological changes in 35 pa-
tients with interstitial lung disorders including IPF,
CVD-IP, COPBOOP, HP and Pneumocystis jiroveci
infection. We only examined BALF samples from
CVD-IP patients who showed typical NSIP patterns as
described in METHODS.
We found that the concentrations of galectin-3 in
BALF were significantly higher in patients with IPF
and CVD-IP than in the control [control (n = 6): 3.19 ±
1.6; IPF (n = 8): 24.3 ± 14.4, p < 0.005 vs. control;
CVD-IP (n = 17): 12.0 ± 5.44 ngml, p < 0.001 vs. con-
trol)] (Fig. 1A). CVD-IP consisted of various entities
and showed similar galectin-3 concentrations [vascu-
litis syndrome (n = 5): 15.3 ± 9.51; dermatomyositis
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Fig. 1 (A) Levels of galectin-3 in the BALF from patients with IPF (n＝ 8), CVD-IP (n＝ 17), control 
[healthy site of lung cancer] (n＝6), and other interstitial lung diseases (n＝10). Galectin-3 concentration 
was measured by specific ELISA as described in METHODS. (B) Immuno-fluorescence microscopic analy-
sis of galectin-3 expression in alveolar macrophages from the BALF of patients. Figure 1B shows represen-
tative distal images of the cels from control and IPF patients. (C) Immunoblot analysis of galectin-3 
expression in U937 cels. Galectin-3 was induced by stimulation with TNF- α and IFN- γ.
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(n = 4): 12.6 ± 1.55; undifferentiated connective tissue
disease (UCTD) (n = 4): 10.4 ± 2.67; rheumatoid ar-
thritis (RA) (n = 2): 11.3 ± 4.46; systemic sclerosis
(SSc) (n = 2): 10.2 ± 1.86; Sjogren’s syndrome (SjS)
(n = 2): 9.18 ± 0.689 ngml]. Patients with other inter-
stitial lung diseases including COPBOOP (n = 5),
hypersensitive pneumonia (n = 3) and Pneumocystis
jiroveci infection (n = 2) showed no significant differ-
ences in galectin-3 concentration (3.13 ± 2.05 ngml,
n = 10; Fig. 1A) compared with control. We rectified
galectin-3 concentration by total protein concentra-
tion, total cell number, and macrophage number of
BALF, and found that this protein was significantly in-
creased independent of these factors in IPF and CVD-
IP patients (data not shown).
Immunofluorescence microscopic analysis re-
vealed that alveolar macrophages from IPF patients
expressed more galectin-3 inside the cells than con-
trol subjects (Fig. 1B), suggesting that the increased
galectin-3 concentration in BALF was, at least partly,
produced by alveolar macrophages. An increase in
galectin-3 inside the cells was also observed in CVD-
IP, but it was not always significant (data not shown).
To determine whether galectin-3 expression is af-
fected by disease activity, we also measured its con-
centration in BALF from patients with IPF (n = 3) and
CVD-IP (n = 2; dermatomyositis and UCTD), who
had improved or showed no obvious progression of
the disease after corticosteroid therapy (0.3―1.0 mg
kg of prednisolone) for more than 4 weeks. We found
that galectin-3 concentration seemed to be lower in
these patients than in the untreated group [treated
Galectin-3 in Pulmonary Fibrosis
Allergology Internatinal Vol 56, No1, 2007 www.jsaweb.jp 61
TNF-α
G3PDH
IL-8
control Gal3 LPS Gal3＋LPS
A
Fig. 2 Detection of TNF-α and IL-8 mRNA (A) and protein secretion (B) in human macro-
phage cel line, THP-1 using RT-PCR and ELISA assay, respectively. Cytokine secretion 
was adjusted by LPS-induced protein concentration, and expressed as % of production.
0
50
100
150
200
control gal3 LPS gal3＋LPS control gal3 LPS gal3＋LPS
0
400
200
600
%
 o
f T
N
F
-α
 p
ro
d
u
ct
io
n
TNF-α
%
 o
f I
L-
8 
pr
od
uc
tio
n
IL-8
B
CVD-IP (n = 2): 1.93 ± 2.73; treated IPF (n = 3): 4.82 ±
2.21; total: 3.66 ± 2.61 ngml], although it was not sta-
tistically significant.
To determine whether galectin-3 is inducible, we
stimulated a monocytic cell line U937, which does not
express detectable amounts of galectin-3 in resting
state, with several cytokines. We also used another
macrophage cell line THP-1, but it was hard to exam-
ine, because galectin-3 was constitutively expressed
(data not shown). Western blotting showed that
stimulation of U937 by TNF-α induced galectin-3 ex-
pression after 24 hours (Fig. 1C). Interestingly, an
anti-fibrotic cytokine IFN-γ also stimulated the cells to
express galectin-3 (Fig. 1C). In contrast, profibrotic
cytokines including IL-4, IL-13 or TGF-β did not affect
galectin-3 expression in this assay (data not shown).
These results suggest that the specific increase of
galectin-3 in the BALF and alveolar macrophages
from patients with IPF and CVD-IP is probably a re-
sult of stimulation by proinflammatory cytokines.
Galectin-3 induces TNF-α and IL-8 production in
macrophages. We hypothesized that increased lung
galectin-3 may in turn stimulate resident cells by
autocrine and paracrine mechanisms to produce
profibrotic factors in the lung. We used PMA-
differentiated human macrophage cell line THP-1 on
a more actual state of the cells as described in
METHODS. By using a RT-PCR, we found that
galectin-3 stimulated THP-1 macrophages to increase
TNF-α and IL-8 mRNA after 1 hour as well as LPS did
(Fig. 2A). Galectin-3 and LPS seemed to act additively
to induce mRNA expression after 1 hour. ELISA as-
say also showed that galectin-3 significantly increased
secretion of TNF-α and IL-8 from THP-1 compared
with control, and the amounts of released cytokines
in the supernatant after 24 hours were 4.8 and 1.2
times, respectively, higher than the level induced by
LPS [TNF-α; 476 ± 156%; IL-8; 120 ± 28.8% (n = 4)]
(Fig. 2B). Interestingly, stimulation of the cells with a
combination of galectin-3 and LPS did not reach the
levels of cytokine production induced by galectin-3
alone [TNF-α; 96.5 ± 3.65%; IL-8; 180 ± 32.1%, n = 4]
(Fig. 2B). We also found that galectin-3 did not in-
duce detectable amounts of IL-4, IL-13 or TGF-β pro-
duction in this cell line within 24 hour-stimulation
(data not shown). These results suggest that in-
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Fig. 3 (A) The efect of galectin-3 on fibroblast cel migration in vitro. Control vehicle, Galectin-3 (1 or 10 
μM), or PDGF (10 ng/ml) were applied to the lower chambers, NIH-3T3 cels were applied on the membra-
ne, and migration assay was performed as described in METHODS. Data are means ± SD of four individ-
ual experiments. (B) The efect of galectin-3 on colagen synthesis by fibroblasts. After NIH-3T3 cels 
were stimulated with 100 μM galectin-3, IL-4 (100 IU/ml), or both reagents for 48 hours, cel culture me-
dium was harvested and soluble colagen was measured according to the manufacturer’ sinstructions. 
Data are means ± SD of four individual experiments.
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creased galectin-3 may participate in lung fibrosis by,
at least partly, activation of resident macrophages to
produce TNF-α and IL-8, thereby sustaining inflam-
mation and fibrosis in the lung.
Galectin-3-induced migration and collagen produc-
tion in fibroblasts. As galectin-3 shows chemotactic or
chemokinetic activity for various types of cell,28,35 we
examined whether galectin-3 attracts fibroblasts to in-
itiate lung fibrosis. We first confirmed that PDGF sig-
nificantly increased NIH-3T3 fibroblast cell migration
compared with control in a modified Micro Boyden
chamber assay (vehicle only: 0.77 ± 0.37%, 10 ngml
PDGF: 40.1 ± 13.9%; p < 0.01, n = 4 experiments). Us-
ing this assay, we showed that galectin-3 also signifi-
cantly increased migration of NIH-3T3 at concentra-
tions of 10 μM, and even 1 μM of the protein seemed
to enhance cell migration, although it was not statisti-
cally significant [1 μM Galectin-3: 5.45 ± 2.34%; 10 μM
galectin-3: 14.2 ± 6.89%; p < 0.05, n = 4] (Fig. 3A).
Sircol assay showed that galectin-3 induced colla-
gen production by NIH-3T3 cells into the supernatant
after 48 hours (control: 1.13 ± 1.95 mgml, 100 μM
Galectin-3: 21.0 ± 8.3 mgml; p < 0.01, n = 4) (Fig. 3
B). The effect of galectin-3 was almost the same as
that of 100 Uml IL-4, a positive control of profibrotic
cytokine. Combination of galectin-3 and IL-4 did not
significantly exceed the effect of collagen synthesis
by single stimulation, suggesting a common pathway
of signal transduction, or its effect reached its maxi-
mum at that concentration. These results suggest
that galectin-3 may directly participate in fibrogenesis
by recruiting and stimulating the fibroblasts to syn-
thesize collagen at the site.
DISCUSSION
In this report, we showed that galectin-3 was in-
creased in the BALF from patients with fibrotic lung
diseases including IPF and CVD-IP, compared with
control BALF (Fig. 1A). The up-regulation of galectin-
3 appears to be specific for these pulmonary fibrotic
disorders, because patients with other interstitial
lung diseases such as COPBOOP, acute hypersensi-
tive pneumonia, and Pneumocystis jiroveci infection
did not show any significant increment of this protein
in the BALF (Fig. 1A). Among various IIPs, we have
analyzed BALF samples only from IPF and COP
BOOP but not from other entities. Thus, it is not yet
determined whether galectin-3 is increased or not in
other non-IPF IIPs. So far, we have only preliminary
data that galectin-3 seemed to be slightly increased in
BALF from (non-CVD-IP) NSIP patients, although it
was not statistically significant compared with control
[NSIP: 8.02 ± 3.77 ngml, (n = 6)]. On the other hand,
it is well known that IPF is resistant to conventional
immunosuppressive therapy,1 but COPBOOP is
generally a steroid-responsive organizing pneumonia.
Taken together, these results suggest that increased
galectin-3 in the lung might be related to lung fibrosis
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and disease obstinacy for immunosuppressive thera-
pies. In addition, we showed that galectin-3 levels
seemed to be lower in patients with CVD-IP receiving
corticosteroid therapy, although it was not statisti-
cally significant. Thus, it may be useful to examine
the galectin-3 level in BALF for not only diagnosis but
also for assessing the response to medical treatment
in cases of lung fibrosis.
The source of increased galectin-3 seemed to be, at
least partially, derived from alveolar macrophages,
which were shown to contain more galectin-3 inside
the cells from IPF patients than in those from control
subjects (Fig. 1B). Increased galectin-3 in the BALF
of fibrotic lung disease is probably induced by proin-
flammatory cytokines, because its expression was in-
duced in vitro in a monocytemacrophage cell line
U937 by stimulation with TNF-α (Fig. 1C), one of the
key cytokines of lung fibrosis.4-7
We also propose that increased galectin-3 in BALF
is related to the pathogenesis of lung fibrosis, be-
cause of its ability to induce TNF-α production by
macrophages (Fig. 2A, B), suggesting a positive feed-
back mechanism between TNF-α and galectin-3 to
sustain inflammation. It seemed curious that galectin-
3 did not act additively with LPS for the secretion of
cytokines unlikely to the mRNA induction pattern
(Fig. 2A, B). This phenomenon may be explained by
the fact that galectin-3 binds to LPS directly46 to in-
hibit interaction of LPS with its cell surface receptors.
Alternatively, it is possible that galectin-3 may inhibit
the apoptotic pathway33 by starvation in this assay
contrary to LPS, which can induce apoptosis in
macrophages.48 Although we found no significant dif-
ference in numbers of cells within 24 hours by any
stimulation, it is conceivable that galectin-3 might
keep cell viability, resulting in continuous secretion
of these cytokines. Further studies are required to
determine the precise mechanism of this issue.
We also examined the correlation of BALF
galectin-3 and serum KL-6, which is a frequently used
marker to predict the outcome of IPF.49 Both
galectin-3 and KL-6 increased in 5 of all 7 patients ex-
amined, but only galectin-3 showed high levels in 2
patients. The latter cases consisted of IPF and CVD-
IP with dermatomyositis (Galectin-3; 14.1 and 11.0
ngml, respectively), and showed radiologically obvi-
ous honeycombing and ground glass opacity, respec-
tively. We also encountered a steroid-responsive pa-
tient with COPBOOP with high KL-6 (1080 Uml)
and normal galectin-3 in BALF (2.61 ngml) before
treatment. Although the number of cases is too small
to draw a definite conclusion, BALF galectin-3 might
be more specific than serum KL-6 for lung fibrosis.
Previous studies have demonstrated that profi-
brotic cytokines including TGF-β, IL-4, and IL-13 are
also probably the key mediators as well as proinflam-
matory cytokines in the pathogenesis of pulmonary fi-
brosis,8,9,13 suggesting that Th2 type immune re-
sponses also play central roles in the fibrotic process.
In a mouse model, administration of IFN-γ, a Th1 type
cytokine, ameliorated bleomycin-induced lung fibro-
sis via IP-10 induction and inhibition of TGF-β pro-
duction.40,41 Based on this concept, a clinical trial of
IFN-γ1b therapy was conducted, and the therapy
seemed to decrease the mortality of IPF patients.42
Nevertheless, IFN-γ treatment did not improve physi-
ological parameters after one-year therapy in a large
clinical trial,43 and did not suppress profibrotic mo-
lecular expression at 6 months.44 Moreover, this ther-
apy was reported to induce acute respiratory failure
in several patients with advanced stage lung fibro-
sis.45 One possible explanation for the discrepancy is
that IFN-γ has dual opposing effects; one is down-
regulation of fibrosis as described above, and another
is activation of the inflammatory pathway to promote
fibrosis. As shown in this study, we speculate that
IFN-γ-induced galectin-3 production from alveolar
macrophages may enhance lung fibrosis by inducing
TNF-α. Therefore, we propose that a combination of
IFN-γ therapy with galectin-3 blockade may be a
promising approach to prevent progression of lung fi-
brosis in IPF and CVD-IP.
We also propose one more possibility that galectin-
3 is involved in lung fibrosis by inducing angiogene-
sis. The existence of extensive neovascularization in
IPF was already reported by Turner-Warwick in
1963,47 and a recent study revealed an imbalance in
levels of CXC chemokines in IPF.14 These chemokine
family members containing the ELR (Glu-Leu-Arg)
motif, including IL-8, are potent promoters of angio-
genesis at physiologic concentrations of 1 to 100
nM.14 In contrast, IFN-inducible members of the
chemokine lacking the ELR motif, such as IP-10, are
in general potent angiostatics at physiologic concen-
trations of 500 pM to 100 nM.14 Indeed, IP-10 has
been reported to attenuate lung fibrosis induced by
bleomycin via inhibition of angiogenesis,41 indicating
the importance of chemokines and neovascularization
in the disease. We found that galectin-3 stimulates
macrophages to induce an angiogenic CXC
chemokine, IL-8 (Fig. 2A, B). Its concentration in the
supernatant of the in vitro experiments was around
100 pM (data not shown), suggesting that local con-
centration of the chemokine can reach 1 to 100 nM.
Moreover, Raz and coworkers found that galectin-3
directly stimulated capillary tube formation of endo-
thelial cells in vitro and induced angiogenesis in
vivo.28 Although we did not examine the effects of
galectin-3 on the expression of other CXC chemoki-
nes such as IP-10, it is possible that this lectin may
participate in vascular remodeling in IPF by acting di-
rectly on endothelial cells and indirectly through IL-8
production.
Finally, we found that galectin-3 induced migration
and collagen synthesis of fibroblasts in vitro, suggest-
ing direct effects of this protein on fibrogenesis (Fig.
Nishi Y et al.
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3A, B). Our previous study showed that galectin-3 in-
duced chemotactic activity and Ca2+ influx in mono-
cytesmacrophages via its carbohydrate-binding ac-
tivity.27 Therefore, the phenomenon may have arisen
by a similar mechanism in the case of fibroblasts, and
these pathways are the subject of our on-going inves-
tigation. Taking together these results, this study is
the first to propose that galectin-3, a galactose-
binding animal lectin, plays an important role in the
development of lung fibrosis by interacting with vari-
ous cytokines and chemokines.
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